Prior to co-founding Tracer Biotechnologies Mark was the CEO and co-founder of SolveBio (acquired by Precision Medicine Group). Mark received his PhD in Genetics from Stanford University and AB in Biochemistry and Computer Science from Harvard University.
Gopal is the co-founder and CSO of Tracer Biotechnologies. Previously he served as CTO of Wellframe (acquired by Blackstone). Gopal completed his postdoctoral work at the Broad Institute and received his PhD in Mathematics from MIT and MD from Harvard Medical School.
Dr. Barrett served as the SVP of Translational Medicine, Oncology at AstraZeneca and VP and Global Head of Biomarkers and Imaging at Novartis. Currently, Dr. Barrett serves as the Chief Scientific Officer of Precede Biosciences.
Dr. Eliezer (Eli) Van Allen is an Associate Professor of Medicine at Harvard Medical School, Chief of the Division of Population Sciences at the Dana-Farber Cancer Institute, an Institute Member at the Broad Institute of MIT and Harvard, and a Member Researcher in The Parker Institute for Cancer Immunotherapy at Dana-Farber Cancer Institute.
Dr. Braunstein is an Associate Attending in the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center (MSKCC) and serves as Program Director of the Radiation Oncology Residency Training Program. He is the PI of the HERO trial (NRG BR008), an international phase III randomized study that aims to optimize radiotherapy for early stage HER2-positive breast cancer and Clinical Co-Chair of the RADCOMP trial, a large-scale, multi-center, randomized study evaluating photon versus proton therapy for breast cancer patients. Dr. Braunstein is an internationally recognized leader in breast cancer radiation oncology, with his research significantly advancing our understanding of personalized radiotherapy approaches. Dr. Braunstein serves as a Board Examiner for the American Board of Radiology in radiation oncology and as an Associate Editor for the Red Journal.
Dr. Jacob Berchuck is a board-certified Medical Oncologist and Assistant Professor of Medical Oncology at the Winship Cancer Institute of Emory University. Previously, Dr. Berchuck served as an Assistant Professor of Medicine at Harvard Medical School and a Medical Oncologist at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital. Dr. Berchuck leads a translational research lab focused on using novel liquid tools to develop circulating biomarkers to guide treatment decisions and decipher mechanisms of therapeutic resistance.
Alex serves the board of Ryght (GenAI for clinical trials), Gencove (low pass NGS) and ChromaCode (molecular diagnostics). Previously Alex was a board member at PRA Health Sciences, acquired by ICON plc for $12B. Earlier he was an SVP at Illumina after it acquired his qPCR startup, Helixis, for $105M.
Garret is the former President of the Clinical Sequencing and Oncology Division at Thermo Fisher Scientific, where he led a multidisciplinary Division focused on the development and commercialization of rapid NGS testing in oncology. Prior to that Garret was SVP, Clinical Genomics at Illumina, leading the development of NGS tests in oncology, reproductive health and rare genetic disease. He has held multiple executive leadership roles in Pharma at Genentech & Roche, Celgene, and Novartis leading translational medicine, integrating knowledge of disease biology to enable clinical oncology drug development. Garret serves as an Independent Director at Ideaya Biosciences Inc., (NASDAQ: IDYA) a clinical stage oncology company; a member of the Dean’s Advisory Council at UC San Diego’s School of Biological Sciences; an advisor to several biotech companies, as well as an advisor for private capital investments.
Dr. Alex Parker has broad experience as a board member, advisor, and executive at pivotal genomics and early detection ventures. Among other roles, Alex served as VP of Business Development at Foundation Medicine, SVP of Clinical Product Strategy at Thrive Earlier Detection Corp, and Board Member of C2i Genomics. Currently, Alex serves on the board of several companies in the genomics and pathology space and is a Strategic Advisor to Earli, inc., Mursla Bio, Casdin Capital, and Tracer Biotechnologies.
Prior to advising Tracer on IP Strategy, Bill was a law firm partner and senior executive of publicly traded companies, including Guardant Health and Fluidigm. Bill advises biotech start-ups on intellectual property matters, including building comprehensive patent portfolios, as well as implementing offensive and defensive patent strategies on a worldwide basis.
Tracer is a U.S.-based biotechnology company specializing in the detection of cancer through molecular markers.
